Shuwen Cao
YOU?
Author Swipe
View article: Understanding Structural Changes in Recycled Aggregate Concrete under Thermal Stress
Understanding Structural Changes in Recycled Aggregate Concrete under Thermal Stress Open
Objective: This study investigates the influence of high-temperature treatment on the deformation properties and structural deformation of recycled aggregate concrete (RAC) in response to potential fire hazards in the construction industry…
View article: Data from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Data from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
Globally, hepatocellular carcinoma (HCC) is one of the most commonly diagnosed cancers and a leading cause of cancer-related death. We previously identified an immune evasion pathway whereby tumor cells produce retinoic acid (RA) to promot…
View article: Supplementary Table 2 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Table 2 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
Table comparing various key pharmacokinetic parameters (Assay, left column) between C-91 and C-86.
View article: Supplementary Figure S5 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Figure S5 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
Supplementary Figure
View article: Supplementary Data Legends from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Data Legends from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
Legends for supplementary figures and tables.
View article: Supplementary Figure S5 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Figure S5 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
Supplementary Figure
View article: Supplementary Figure S6 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Figure S6 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
Supplementary Figure
View article: Supplementary Table 5 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Table 5 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
Tissue pharmacokinetics and bio-distribution of C86 at two different does through the intraperitoneal route.
View article: Supplementary Figure S7 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Figure S7 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
Supplementary Figure
View article: Supplementary Table 3 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Table 3 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
Safetyscreen assay for C86 performed at eurofins.
View article: Supplementary Figure S1 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Figure S1 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
Supplementary Figure
View article: Supplementary Figure S6 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Figure S6 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
Supplementary Figure
View article: Supplementary Figure S7 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Figure S7 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
Supplementary Figure
View article: Supplementary Table 4 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Table 4 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
Plasma pharmacokinetic comparisons of C86, C91, and C99 in mice for parameters outlined in the table.
View article: Supplementary Table 2 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Table 2 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
Table comparing various key pharmacokinetic parameters (Assay, left column) between C-91 and C-86.
View article: Supplementary Table 1 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Table 1 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
List of key reagents
View article: Supplementary Figure S2 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Figure S2 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
Supplementary Figure 2
View article: Supplementary Table 5 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Table 5 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
Tissue pharmacokinetics and bio-distribution of C86 at two different does through the intraperitoneal route.
View article: Supplementary Figure S4 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Figure S4 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
Supplementary Figure
View article: Supplementary Figure S3 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Figure S3 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
Supplementary Figure
View article: Supplementary Figure S4 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Figure S4 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
Supplementary Figure
View article: Supplementary Table 4 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Table 4 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
Plasma pharmacokinetic comparisons of C86, C91, and C99 in mice for parameters outlined in the table.
View article: Supplementary Figure S2 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Figure S2 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
Supplementary Figure 2
View article: Supplementary Figure S1 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Figure S1 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
Supplementary Figure
View article: Supplementary Table 1 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Table 1 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
List of key reagents
View article: Supplementary Figure S3 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Figure S3 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
Supplementary Figure
View article: Data from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Data from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
Globally, hepatocellular carcinoma (HCC) is one of the most commonly diagnosed cancers and a leading cause of cancer-related death. We previously identified an immune evasion pathway whereby tumor cells produce retinoic acid (RA) to promot…
View article: Supplementary Data Legends from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Data Legends from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
Legends for supplementary figures and tables.
View article: Supplementary Table 3 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Table 3 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
Safetyscreen assay for C86 performed at eurofins.
View article: RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma Open
Globally, hepatocellular carcinoma (HCC) is one of the most commonly diagnosed cancers and a leading cause of cancer-related death. We previously identified an immune evasion pathway whereby tumor cells produce retinoic acid (RA) to promot…